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I patients reported on symptoms of constipation during the
preceding year.1 Opioid intake increased the odds for consti-
pation by factor 1.6 representing the most important side effect
Therefore, this stu
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Abstract: Constipation is a prevalent comorbidity affecting 50% of
patients with long-term opioid therapy. In clinical routine different
diagnostic instruments are in use to identify patients under risk. The aim
of this study was to assess the diagnostic performance of an 11-item
Likert scale for constipation used as a self-assessment in opioid-treated
patients.
This trial was conducted as a retrospective cohort study in Berlin,
Germany. Patients with long-term opioid therapy treated in 2 university-
affiliated outpatient pain facilities at the Charite´ hospital were included
from January 2013 to August 2013. Constipation was rated in a self-
assessment using a numeric rating scale from 0 to 10 (Con-NRS) and
compared with results from a structured assessment based on ROME-III
criteria.
Altogether, 171 patients were included. Incidence of constipation
was 49% of patients. The receiver-operating characteristic of Con-NRS
achieved an area under the curve of 0.814 (AUC 95% confidence
interval 0.748–0.880, P< 0.001). Con-NRS  1 achieved sensitivity
and specificity of 79.7% and 77.2%, respectively. The positive pre-
dictive value and the negative predictive value were 70.3% and 81.6%,
respectively.
Overall diagnostic performance of a concise 11-item Likert scale for
constipation was moderate. Although patients with long-term opioid
therapy are familiar with numeric rating scales, a significant number of
patients with constipation were not identified. The instrument may be
additionally useful to facilitate individualized therapeutic decision
making and to control therapeutic success when measured repetitively.
(Medicine 94(50):e2227)
Abbreviations: AUC = area under the curve, NRS = numeric rating
scale, ROC = receiver-operating characteristic.
INTRODUCTION
n a large observational study in the USA altogether 18.9% ofdia Denke, PhD, T user, MD,
MD, and Michael Scha¨fer, MD, PhD
of these drugs.2 Affected patients experience a significant
impairment in quality of life 3 and constipation is one of the
main reasons to change prescribed therapy.4–6 Focusing
patients with long-term opioid therapy, the incidence of con-
stipation reaches 30% to 50% and a number-needed-to-harm
of 3.4 was described.2,7
The current gold standard for diagnosing functional con-
stipation is using ROME–III criteria.8 Accordingly, patients are
required to assess only frequency of defecations (<3 per week),
straining during defecation, lumpy or hard stools, sensations of
incomplete evacuation or of anorectal obstruction and, whether
manual maneuvers are required. With 2 or more of these criteria
functional constipation is diagnosed. Also, the need for laxa-
tives to achieve loose stool is incorporated into these criteria.8
Even though gastrointestinal symptoms are common side
effects of opioids, it might be conflicting for patients to report
symptoms. Consequently, alternative tools were developed to
support diagnosing of constipation.9 Therefore, simple and
reliable screening instruments were searched.10,11 Patients
receiving opioid medication are very familiar with the use of
Likert scales like the numeric analogue scale for pain. This scale
has also been validated to assess other symptoms such as nausea
12 and is part of validated standardized screening questionnaires
for anxiety and depression.13,14 Similarly, an 11-item version of
the scale was described to assess constipation. This scale was
validated in patients with advanced cancer by Rhondali et al and
in a sample of palliative patients by Noguera et al.15,16 In both
studies, diagnostic test performance was sufficient with sensi-
tivity >80% but a significant number of patients were not
detected. However, this 11-point Likert screening instrument
for constipation has not yet been validated in a general popu-
lation of patients with long-term opioid therapy.diagnostic test characteristics of the screening instrument for
opioid-induced constipation.
MATERIALS AND METHODS
This study was performed as a retrospective cohort study
including all consecutive patients presenting in 2 hospital-
affiliated specialized outpatient pain centers in Berlin,
Germany. Patients were screened during January and August
2013 for inclusion criteria; these were defined as age of at least
18 years and current oral or transdermal opioid therapy for at
least 4 weeks. Patients were excluded for analysis with evidence
of comorbidity that significantly influenced stool frequency, eg
patients with inflammatory bowel diseases.
Data were obtained from the electronic patient chart in the
hospital mainframe computer and also based on the written
documentation of clinical care in the study centers. Supervisedrmed by 2 investigators (FB, TB) using a
atient report form. Dosing of current
transferred in oral morphine equivalents
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To assess test characteristics for Con-NRS in the study
population, patients were grouped according to ROME-III
criteria as the gold standard for diagnosis of constipation.
TABLE 1. Basic Characteristics of Study Population (N¼171
Patients)
Main Pain Modality N (%)
Back pain 76 (44%)
Musculoskeletal pain 36 (21%)
Rheumatic pain 35 (20%)
Tumor-associated pain 13 (7%)
Abdominal pain and others 5 (3%)
Gender, females N (%) 96 (56%)
Age, median years (range) 63 (25–90)
Opioid agent N (%)
Hydromorphone [1:7.5] 37 (22%)
Tapentadol [2.5:1] 35 (20%)
Oxycodone/Naloxone [1:2] 32 (19%)
Morphine [1:1] 23 (13%)
Fentanyl [1:100] 18 (11%)
Others (eg, Tilidin or Tramadol: 10:1) 26 (15%)
Transdermal opioid application, N (%) 24 (14%)
Co-medication antidepressants, N (%) 104 (61%)
Oral morphine equivalents in mg/day,
median (range)
90 (10 – 600)





For conversion of opioids to morphine equivalents, factors are
FIGURE 1. Flow chart for patient inclusion. Con-NRS – numeric
rating scale from 0-10 for constipation; ROME-III – criteria for
constipation: patients are diagnosed with constipation when ful-
filling two or more of the criteria (frequency of defecations (<3 per
Tafelski et albased on the German S3-guideline for Long-Term Opioid Use
in Non-Cancer Pain 2014 (see also Table 1).17,18 During his first
consultation, every patient provided information filling a stan-
dardized questionnaire adapted from the nationally recom-
mended German pain questionnaire.19 This also addressed
potential side effects of opioids. Constipation was rated from
all patients in a self-assessment using a numeric rating Likert
scale from 0 to 10 (Con-NRS, 0 ‘‘no problems’’ to 10 ‘‘worst
possible symptom’’). Additionally, symptoms of constipation
were evaluated in a structured assessment based on ROME-III
criteria serving as the gold standard to define constipation.8 This
was performed by the attending pain specialists during the
patient visit.
For statistical analyses SPSS version 22 was used. Descrip-
tive data were summarized depending on the scale level and
distribution using mean and standard deviation or median and
range. For the evaluation of test performance, the area under the
curve of the receiver-operating characteristic (AUC of ROC)
was calculated. The rating scale was intended to be used as a
screening instrument which requiresmaximized sensitivity. Con-
sequently, based on results of the ROC analysis, the optimal cut-
off with maximized sensitivity was searched. For this test value,
sensitivity, specificity, positive predictive values, and negative
predictive values were calculated. Con-NRS could also be of
value to assess symptom severity from the subjective patient
perspective. Therefore, a correlation between the summed num-
ber of symptoms of ROME-III items and the numeric rating scale
was calculated and assessed by Kendall’s tau. Additionally,
logistic regression analysis was performed. For statistical sig-
provided in square brackets (eg 4mg of oral hydromorphone is equal
to 30mg of oral morphine).nificance analyses a 2-sided alpha level of <5% was defined.
This study was approved by the institutional review board
of Charite´ university hospital and the local data safety board.
2 | www.md-journal.comMedicine  Volume 94, Number 50, December 2015Due to the observational nature of the trial the review board
waived the need for informed consent.
RESULTS
During the study period 1166 patients were screened with
171 fulfilling the inclusion criteria. Most patients were excluded
as opioid therapy was not applied or prescribed for<4 weeks or
history of diseases influenced stool frequency (Fig. 1).
Baseline characteristics of included patients are displayed
in Table 1. Altogether 56% of the study population was women;
median age was 63 years. Most common diagnoses for pres-
entation were chronic back pain, musculoskeletal pain, or
neuropathic pain.
Based on ROME-III criteria, 24 patients reported on 2 or
more symptoms of constipation (14%), and 60 patients achieved
sufficient symptom control using laxatives (35%). The remain-
ing 87 patients (51%) did not fulfill the criteria of ROME-III for
functional constipation. Interestingly, 39 of these 87 patients
reported on episodes of constipation in their past medical
history that was currently not present. Risk for constipation
was significantly associated with increasing dose of morphine
equivalents resulting in an OR of 1.065 (95% confidence
interval 1.023–1.109 for increasing morphine equivalence dose
by 10mg; P¼ 0.002).
Self-Reported Constipation (Con-NRS) and Test
Characteristics
Altogether 92 patients reported a Con-NRS of 0 (53.8%),
whereas 20 patients scaled their current Con-NRS with 8
points (11.7%). When dichotomizing the study population
according to ROME-III criteria mean Con-NRS differed sig-
nificantly between groups. Median Con-NRS in ROME-III
negative patients was 0 (range 0–8) compared with 3.5 (range
0–10) in Rome-III positive patients (P< 0.001).week), straining during defecation, lumpy or hard stools, sen-
sations of incomplete evacuation or of anorectal obstruction and,
whether manual manoeuvres are required or laxative use for
symptom control).8
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The corresponding receiver-operating characteristic of Con-
NRS achieved an area under the curve of 0.814 (AUC 95%
confidence interval 0.748 – 0.880, P< 0.001; Fig. 2).
With the intention to use Con-NRS as a screening instru-
ment, the sensitivity of the test should be optimized to reduce
false-negative results. With a threshold of Con-NRS  1,
sensitivity and specificity achieved 79.7% and 77.2%, respect-
ively. Here, the positive predictive value and negative predic-
tive value achieved 70.3% and 81.6%, respectively. Notably, 21
patients (12.3%) in this study population did report a Con-NRS
of 0 but fulfilled ROME-III criteria for constipation.
Additionally, we observed a positive significant corre-
lation between number of ROME-III symptoms and Con-
NRS with a correlation coefficient of 0.751 (P< 0.01).
DISCUSSION
In this study including patients with long-term opioid
medication a simple 11-item self-assessment scale for consti-
pation achieved a sensitivity of 80% and moderate test
performance. Consequently, the scale may be useful as an
assessment tool to facilitate an individualized patient decision
process in the management of potential medication-associated
side effects. Notably, 21 patients were not identified with this
instrument. The complex constellation of alternating and long-
lasting symptoms of constipation might not be detected with this
Medicine  Volume 94, Number 50, December 2015screening instrument entirely. Even though gastrointestinal
symptoms are common side effects of opioids, it might be
conflicting for patients to report such symptoms. Consequently,
FIGURE 2. Evaluation of test performance of Con- NRS with
Rome-III criteria as gold standard, receiver operating characteristic
with area under the curve of 0.814 (95% confidence interval
0.748 – 0.880, p<0.001). Patients are diagnosed with consti-
pation when fulfilling two or more of the ROME-III – criteria for
constipation: patients are diagnosed with constipation when ful-
filling two or more of the criteria (frequency of defecations (<3 per
week), straining during defecation, lumpy or hard stools, sen-
sations of incomplete evacuation or of anorectal obstruction and,
whether manual manoeuvres are required or laxative use for
symptom control).8
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ated constipation occurs in a large number of patients once
during treatment, patient education is highly important in every
patient contact. The prevalence of constipation was 49% out of
171 patients: 14% of patients reported symptoms of consti-
pation despite laxative use and altogether 35% of patients
reported sufficient symptom control with laxatives. Consti-
pation as a side effect of opioid therapy is well known. Most
notably, patients on opioid therapy are typically not developing
tolerance against this gastrointestinal side effect over time.20 It
is necessary to address this issue in every patient with long-term
opioids for continued patient education and participation.21
Finally, some authors concluded that constipation is inade-
quately assessed and often underdiagnosed.16
Against this background, a simple and feasible screening
instrument could support patient management but should be
able to sufficiently identify patients. Diagnostic screening
instruments need to be tested in different settings to allow an
estimate of diagnostic precision. For example, Rhondali et al
evaluated self-reported constipation with a numeric 11-item
scale in patients with advanced cancer and found a similar
sensitivity of 84% for a cut-off 3 and a specificity of 62%.16
Notably, a false-negative rate of 16% was observed. These
authors also reported that using a single binary question of
constipation (yes/no) had a very high false-negative rate of one-
third. Similarly, Noguera et al evaluated constipation with a
numeric 11-item scale in palliative care patients and 66% of
them treated with opioids. In this trial, the authors described a
sensitivity of 83% and specificity of 63% for the cut-off  2.15
In line with our results, a significant number of patients were not
detected with this numeric rating scale by Noguera et al. The
authors had to conclude that this instrument is not sensitive
enough to diagnose constipation. Unfortunately, validity of
ROME-III criteria was not perfect in specific populations: in
the study of Digesu et al 56 female patients reported on
constipation but only 14% of them were identified by
ROME-III criteria.22 Especially the quantification of symptoms
in the Rome-III criteria is sometimes difficult for patients and
may be 1 reason for diagnostic imprecision.
On the other hand, the use of a numeric rating scale may
provide additional information regarding symptom severity or
associated emotional strain. Exemplarily, Kindler et al reported
that the visual analog scale for pain also correlated with anxiety
or concern of patients.23 Repetitive measurements of a scale
could inform more detailed about therapeutic success and allow
evaluation of therapeutic measures. This aspect could be eval-
uated in further trials.
For clinical care in the context of long-term opioid
therapy, medication-induced constipation is a complication
with a variety of individual signs and symptoms and should
be evaluated in the trustful consultation of patients with
their physicians. Screening instruments may support patient
Con-NRS for Constipation in Opioid Treatmentmanagement but cannot substitute an individualized risk
assessment for constipation and other opioid-related side
effects.
LIMITATION
This observational trial evaluated a limited number of
patients in the specific setting of specialized university hospital
affiliated pain centers. Due to the retrospective nature of the
study it is impossible to infer on causalities and data are limited
to observed variables. Exemplarily, duration of constipation
was not assessed. In contrast, this study evaluated the numeric
www.md-journal.com | 3
constipation scale in a setting where it is intended to be used and
not in an artificial setting of a prospective clinical study. The
latter might increase external validity and larger data sets in
similar setting should be studied to validate the findings.
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